© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
September 18, 2018
In this article, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.
August 15, 2013
Over the past few years, significant efforts have focused on developing and validating molecular biomarkers to better define the subset of patients with stage II disease who might derive benefit from adjuvant therapy.